P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
EuroIntervention · 2023
DOI: 10.4244/eij-d-23-00125 ↗Kurz gefasst
Fachartikel in der Zeitschrift EuroIntervention, 2023. Verfasst von Patricia O Guimarães und 33 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Israelita Albert Einstein, São Paulo, Brazil. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Dual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, particularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open-label trial with a blinded outcome assessment designed to compare SAPT versus DAPT in 3,400 ACS patients undergoing PCI with the latest-generation drug-eluting stents (DES). After successful PCI and up to 4 days following hospital admission, patients are randomised to receive SAPT with a potent P2Y12 inhibitor (ticagrelor or prasugrel) or DAPT (aspirin plus a potent P2Y12 inhibitor) for 12 months. Aspirin is discontinued immediately after randomisation in the SAPT group. The choice between ticagrelor and prasugrel is at the investigator's discretion. The primary hypothesis is that SAPT will be non-inferior to DAPT with respect to the composite endpoint of all-cause mortality, stroke, myocardial infarction or urgent target vessel revascularisation, but superior to DAPT on rates of bleeding defined by Bleeding Academic Research Consortium 2, 3 or 5 criteria. NEOMINDSET is the first study that is specifically designed to test SAPT versus DAPT immediately following PCI with DES in ACS patients. This trial will provide important insights on the efficacy and safety of withdrawing aspirin in the early phase of ACS. (ClinicalTrials.gov: NCT04360720).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Israelita Albert Einstein, São Paulo, Brazil.
- Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, São Paulo, Brazil and Universidade de São Paulo, São Paulo, Brazil.
- Research Center, Clínica do Coração, Aracaju, Brazil.
- Hospital Universitário São Francisco de Assis na Providência de Deus, Bragança Paulista, Brazil.
- Hospital Santa Lucia, Poços de Caldas, Brazil.
- Instituto de Cardiologia de Santa Catarina, São José, Brazil.
Zitieren
APA
Guimarães, P. O., Franken, M., Tavares, C. A. M., Silveira, F. S., Antunes, M. O., Bergo, R. R., Joaquim, R. M., Hirai, J. C. S., Andrade, P. B., Pitta, F. G., Mariani, J., Nascimento, B. R., de Paula, J. E. T., Silveira, M. S., Costa, T. A. O., Dall'Orto, F. T. C., Serpa, R. G., Sampaio, F. B. A., Ohe, L. N., …, & Lemos, P. A. (2023). P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial. EuroIntervention. https://doi.org/10.4244/eij-d-23-00125
Vancouver
Guimarães PO, Franken M, Tavares CAM, Silveira FS, Antunes MO, Bergo RR, et al. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial. EuroIntervention. 2023. doi:10.4244/eij-d-23-00125
BibTeX
@article{Guimares2023,
author = {Guimarães, Patricia O and Franken, Marcelo and Tavares, Caio A M and Silveira, Fabio S and Antunes, Murillo O and Bergo, Ricardo R and Joaquim, Rodrigo M and Hirai, Jessica C S and Andrade, Pedro B and Pitta, Fabio G and Mariani, José and Nascimento, Bruno R and de Paula, João E T and Silveira, Marcos S and Costa, Tiberio A O and Dall'Orto, Frederico T C and Serpa, Renato G and Sampaio, Fernanda B A and Ohe, Louis N and Mangione, Fernanda M and Furtado, Remo H M and Sarmento-Leite, Rogerio and Monfardini, Frederico and Assis, Silvia R L and Nicolau, José C and Sposito, Andrei C and Lopes, Renato D and Onuma, Yoshinobu and Valgimigli, Marco and Angiolillo, Dominick J and Serruys, Patrick W and Berwanger, Otavio and Bacal, Fernando and Lemos, Pedro A},
title = {P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial},
journal = {EuroIntervention},
year = {2023},
doi = {10.4244/eij-d-23-00125}
}
EUVIMED